Caption Management’s Larimar Therapeutics LRMR Stock Holding History

Caption Management’s Portfolio LRMR Stock Details LRMR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$739K	Buy	+164,200	New	+$656K	﹤0.01%	1106
2025 Q4	–	Sell	-1,539,700	Closed	-$4.97M	–	1875
2025 Q3	$4.97M	Buy	1,539,700 +195,100	+15%	+$732K	0.04%	487
2025 Q2	$3.89M	Buy	+1,344,600	New	+$3.11M	0.04%	477
2025 Q1	–	Sell	-25,000	Closed	-$96.8K	–	1823
2024 Q4	$96.8K	Buy	+25,000	New	+$165K	﹤0.01%	1342
2024 Q2	–	Sell	-266,400	Closed	-$2.02M	–	1363
2024 Q1	$2.02M	Buy	+266,400	New	+$2.08M	0.03%	529

Other funds holding LRMR

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Caption Management's LRMR Position: Q1 2026 in Review

Caption Management increased its Larimar Therapeutics (LRMR) stake by 53% in Q1 2026, buying an estimated $878K and bringing the position to 635,024 shares worth $2.86M. The position accounts for 0.02% of the portfolio, ranked #715.

Caption Management first reported a position in LRMR in Q1 2024 and has held it in 5 quarters since. The position peaked at $4.24M in Q3 2025. 162 funds tracked by Wall St. Rank hold LRMR as of Q1 2026.

Caption Management held 635,024 shares of Larimar Therapeutics worth $2.86M as of Q1 2026.
Caption Management bought 219,730 Larimar Therapeutics shares in Q1 2026, an estimated $878K.
Larimar Therapeutics made up 0.02% of Caption Management's portfolio in Q1 2026, its #715 holding.
Caption Management first reported a position in Larimar Therapeutics in Q1 2024 and has held it in 5 quarters since.
Caption Management's Larimar Therapeutics position peaked at $4.24M in Q3 2025.
162 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q1 2026.

Based on Caption Management's 13F filing for Q1 2026, filed 15 May 2026.